Cleared Traditional

K933432 - STAGO FACTOR IX-DEFICIENT PLASMA

K933432 is an FDA 510(k) clearance for STAGO FACTOR IX-DEFICIENT PLASMA, manufactured by American Bioproducts Co.. The device is a Class 2 Hematology device with product code GJT cleared through the Traditional 510(k) pathway after a 124-day FDA review.

K933432 · American Bioproducts Co. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1993
Decision
124d
Days
Class 2
Risk

K933432 is an FDA 510(k) clearance for the STAGO FACTOR IX-DEFICIENT PLASMA. Classified as Plasma, Coagulation Factor Deficient (product code GJT), Class II - Special Controls.

Submitted by American Bioproducts Co. (Parsippany, US). The FDA issued a Cleared decision on November 15, 1993 after a review of 124 days - within the typical 510(k) review window.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7290 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all American Bioproducts Co. devices

FDA 510(k) Submission Details - K933432

510(k) Number K933432 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 14, 1993
Decision Date November 15, 1993
Days to Decision 124 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
11d slower than avg
Panel avg: 113d · This submission: 124d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GJT Device Classification - Class 2, Special Controls

Product Code GJT Plasma, Coagulation Factor Deficient
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7290
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GJT Plasma, Coagulation Factor Deficient

All 74
Devices cleared under the same product code (GJT) and FDA review panel - the closest regulatory comparables to K933432.
FACTOR
K935058 · Sigma Diagnostics, Inc. · Mar 1994
STAGO FACTOR V-DEFICIENT PLASMA
K934605 · American Bioproducts Co. · Mar 1994
STAGO FACTOR II-DEFICIENT PLASMA
K934606 · American Bioproducts Co. · Mar 1994
STAGO FACTOR XII-DEFICIENT PLASMA
K933438 · American Bioproducts Co. · Oct 1993
STAGO FACTOR VII-DEFICIENT PLASMA
K933440 · American Bioproducts Co. · Oct 1993
STAGO FACTOR X-DEFICIENT PLASMA
K933441 · American Bioproducts Co. · Oct 1993